標(biāo)題: Titlebook: Advances in Cancer Biomarkers; From biochemistry to Roberto Scatena Book 2015 The Editor(s) (if applicable) and The Author(s), under exclus [打印本頁(yè)] 作者: Causalgia 時(shí)間: 2025-3-21 18:49
書(shū)目名稱(chēng)Advances in Cancer Biomarkers影響因子(影響力)
書(shū)目名稱(chēng)Advances in Cancer Biomarkers影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Advances in Cancer Biomarkers網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Advances in Cancer Biomarkers網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Advances in Cancer Biomarkers被引頻次
書(shū)目名稱(chēng)Advances in Cancer Biomarkers被引頻次學(xué)科排名
書(shū)目名稱(chēng)Advances in Cancer Biomarkers年度引用
書(shū)目名稱(chēng)Advances in Cancer Biomarkers年度引用學(xué)科排名
書(shū)目名稱(chēng)Advances in Cancer Biomarkers讀者反饋
書(shū)目名稱(chēng)Advances in Cancer Biomarkers讀者反饋學(xué)科排名
作者: malapropism 時(shí)間: 2025-3-21 21:25 作者: 蕁麻 時(shí)間: 2025-3-22 01:45
Biomarkers for Hepatocellular Carcinoma (HCC): An Updatereifende wissenschaftliche Betreuung von mehreren Seiten her erfordern. Die vielf?ltigen Erkenntnisse, die dabei zu verwerten sind, müssen jedoch zu einem einheitlichen Urteilsbild zusammengefügt und in dieser Form bei der Planung und Ausführung berücksichtigt werden, weil andernfalls Fehlschl?ge im作者: 金絲雀 時(shí)間: 2025-3-22 06:10 作者: Anticoagulants 時(shí)間: 2025-3-22 11:32 作者: irradicable 時(shí)間: 2025-3-22 13:18
Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives978-3-7091-7709-9作者: 豐富 時(shí)間: 2025-3-22 19:48 作者: 圓錐體 時(shí)間: 2025-3-22 22:08
The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools978-3-642-52319-9作者: 秘方藥 時(shí)間: 2025-3-23 01:32
Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development978-3-642-88246-3作者: Matrimony 時(shí)間: 2025-3-23 07:17 作者: glans-penis 時(shí)間: 2025-3-23 10:19 作者: Obstruction 時(shí)間: 2025-3-23 14:52
Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects978-3-662-01194-2作者: moratorium 時(shí)間: 2025-3-23 20:54
Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer978-3-662-13040-7作者: GORGE 時(shí)間: 2025-3-24 01:00
The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects978-3-642-94583-0作者: Servile 時(shí)間: 2025-3-24 05:09 作者: interlude 時(shí)間: 2025-3-24 07:06 作者: 彩色 時(shí)間: 2025-3-24 13:33
llen auf unterschiedlichen Wegen gel?st werden, um ein Gefühl für die optimale Herangehensweise entwickeln zu k?nnen. über allem steht das gro?e Ziel, Studierende von Ingenieurstudieng?ngen bestm?glich auf die Statik-Prüfung vorzubereiten..Die Verst?ndnisaufgaben werden erg?nzt durch zwei Formelsamm作者: 得體 時(shí)間: 2025-3-24 17:58 作者: 手榴彈 時(shí)間: 2025-3-24 21:27 作者: Lasting 時(shí)間: 2025-3-24 23:14 作者: 樂(lè)意 時(shí)間: 2025-3-25 04:41
George Hassan PhD, MCIBSE, MIMechE, MIMarE marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. A critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory me作者: 大范圍流行 時(shí)間: 2025-3-25 10:27 作者: 免費(fèi) 時(shí)間: 2025-3-25 12:45 作者: Medicaid 時(shí)間: 2025-3-25 18:16 作者: Kinetic 時(shí)間: 2025-3-25 23:15
https://doi.org/10.1007/978-1-4842-6476-8ven though increased levels of NSE have been reported also in non-small cell lung cancer (NSCLC). The level of NSE correlates with tumour burden, number of metastatic sites and response to treatment..NSE can be also useful at diagnosis of NETs and gastroenteropancreatic (GEP)-NETs..Raised serum leve作者: 狗舍 時(shí)間: 2025-3-26 00:30
Embedded Web Experiences with Tabs,he prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these作者: 山頂可休息 時(shí)間: 2025-3-26 04:19 作者: 紡織品 時(shí)間: 2025-3-26 11:19 作者: 暴發(fā)戶(hù) 時(shí)間: 2025-3-26 15:42
https://doi.org/10.1007/978-3-658-41273-9er tests have been adopted successfully into routine clinical care of oncologic patients..This chapter provides an updated background on biomarkers research in oncology, including biomarkers clinical uses, and discusses the problems of discovery pipeline, biomarkers failures and future perspectives.作者: STIT 時(shí)間: 2025-3-26 17:00
Financial Services and the UK Economy,kers such as the urinary transcripts of PCA3 and TMPRSS-ERG fusion are also discussed. To enable further risk stratification tumor markers are often combined with clinical data (e.g. outcome of DRE) in so-called nomograms. Currently the role of magnetic resonance imaging (MRI) in the detection and staging of prostate cancer is being explored.作者: 衍生 時(shí)間: 2025-3-26 23:03
Build Your Reusable Blazor Library,ion, elaborating on current analytical methodologies for metabolomics measurement and introducing existing software for data analysis. The last part of this chapter deals with the statistical analysis of very large metabolomics datasets and their relevance for cancer biomarker identification.作者: 上下連貫 時(shí)間: 2025-3-27 01:52
https://doi.org/10.1007/978-3-8349-6171-6ely evaluate the ability of the biomarker to predict clinical outcomes. In the end, the biomarker is emphasized to the extent that it is actually predictive. This allows clinical cancer drug developers to manage uncertainty in the validity of biomarkers, leading to maximal value for predictive biomarkers and their associated oncology therapies.作者: jaundiced 時(shí)間: 2025-3-27 07:17
https://doi.org/10.1007/978-1-4302-0500-5alue of serum biomarkers is that they could be biologically relevant and disease-specific to pathophysiologic or pathologic process of disease development. This article provides an update of serum biomarkers for hepatocellular carcinoma (HCC) in risk assessment for early detection through surveillance.作者: lymphedema 時(shí)間: 2025-3-27 10:44 作者: 拋媚眼 時(shí)間: 2025-3-27 14:49 作者: Brocas-Area 時(shí)間: 2025-3-27 19:39
Advances in Cancer Biomarkers978-94-017-7215-0Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: LATER 時(shí)間: 2025-3-27 23:15
https://doi.org/10.1007/978-94-017-7215-0biomarkers; cancer diagnosis; cancer pathophysiology; cancer therapy; metastasis作者: 蘆筍 時(shí)間: 2025-3-28 04:55
978-94-024-0420-3The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature B.V. 201作者: 密切關(guān)系 時(shí)間: 2025-3-28 08:27
Roberto ScatenaContributes to a careful knowledge of the biochemistry, pathophysiology and clinics of cancer biomarkers.Promotes an optimal clinical use of cancer biomarkers.Facilitates the understanding of the real作者: 深陷 時(shí)間: 2025-3-28 12:41
Advances in Experimental Medicine and Biologyhttp://image.papertrans.cn/a/image/146973.jpg作者: 辭職 時(shí)間: 2025-3-28 14:40
George Hassan PhD, MCIBSE, MIMechE, MIMarEnostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some pat作者: 馬籠頭 時(shí)間: 2025-3-28 20:16 作者: UNT 時(shí)間: 2025-3-29 01:39 作者: 強(qiáng)所 時(shí)間: 2025-3-29 04:32
Build Your Reusable Blazor Library, high-throughput technologies, and enhanced computational power, metabolomics has a high potential for cancer biomarker identification and the development of diagnostic tools. This chapter describes current metabolomics technologies used in cancer research, starting with metabolomics sample preparat作者: 不如樂(lè)死去 時(shí)間: 2025-3-29 07:31 作者: 怎樣才咆哮 時(shí)間: 2025-3-29 13:32
https://doi.org/10.1007/978-3-8349-6171-6t part of the future of oncology. They have the potential to reduce the size and cost of clinical development programs for oncology therapy, while increasing their probability of success and the ultimate value of cancer medicines. But predictive biomarkers do not always work, and under these circums作者: MAIM 時(shí)間: 2025-3-29 18:25
Financial Services and the UK Economy,logical and clinical aspects of PSA. The main drawback of total PSA (tPSA) is its lack of specificity for prostate cancer which leads to unnecessary biopsies. Moreover, PSA-testing poses a risk of overdiagnosis and subsequent overtreatment. Many PSA-based markers have been developed to improve the p作者: Ascendancy 時(shí)間: 2025-3-29 22:05
A Brief History of Building Societies,ine measurement in many clinical laboratories. Previous studies where mostly based on investigated LDH in serum of patients with cancer with aims to estimate their clinical significance. The new directions in investigation of LDH where based on the principle that tumor cells release intracellular en作者: 說(shuō)笑 時(shí)間: 2025-3-30 03:05 作者: Peristalsis 時(shí)間: 2025-3-30 05:48
Embedded Web Experiences with Tabs,I-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion 作者: 支架 時(shí)間: 2025-3-30 10:12 作者: 吹牛者 時(shí)間: 2025-3-30 14:00
